Market Place
Sourcing Support
NS Pharma`s Duchenne drug Viltepso flunks confirmatory trial
29 May 2024 //
FIERCE PHARMA
Ns Pharma Viltolarsen Phase 3: Racer53 Preliminary Results Shared
27 May 2024 //
PR NEWSWIRE
NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Conference
06 Mar 2024 //
PR NEWSWIRE
VILTEPSO® (viltolarsen) injection Four-Year Clinical Trial Data Published
09 May 2023 //
PR NEWSWIRE
VILTEPSO injection Open Label Extension Trial Data Scheduled for Presentation
19 Mar 2023 //
PR NEWSWIRE
NS Pharma Reports on Results of VILTEPSO injection
24 Oct 2022 //
PRNEWSWIRE
VILTEPSO injection Four-Year Trial Data to be Presented at World Muscle Society
04 Oct 2022 //
PRNEWSWIRE
VILTEPSO (viltolarsen) injection: Long-Term Efficacy and Safety Data
31 May 2022 //
PRNEWSWIRE
VILTEPSO Interim Long-Term Clinical Trial Data Scheduled for Presentation
17 Sep 2021 //
PRNEWSWIRE
Study Suggests Nerivio® Effective for Acute Menstrual Migraine Headache
21 Jun 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.